Saâda Esma, Follana Philippe, Peyrade Fréderic, Mari Véronique, François Eric
Centre Antoine-Lacassagne, département d’oncologie médicale, Nice, France.
Bull Cancer. 2011 Jun;98(6):679-87. doi: 10.1684/bdc.2011.1373.
Malignant ascites are the cancer-associated accumulation of fluids in the peritoneal cavity. The neoplasms most frequently associated with ascites are ovarian, breast, colon, stomach and pancreas adenocarcinomas. Symptoms are abdominal distention, nausea, vomiting, anorexia, dyspnea and limbs oedemas. Several pathophysiological mechanisms might be implicated such as peritoneal carcinomatosis, lymphatic vessels' obstruction, portal hypertension or heart failure. Its diagnosis is most often performed in a context of already known neoplasia. Malignant ascites are associated with a pejorative evolution. Ascites which cannot be mobilized or show early recurrence and cannot be prevented by medical treatment are defined as refractory ascites. Therefore, management of refractory malignant ascites takes place in the context of palliative care and aims at improving the quality of life of these patients. This review lists the current data reported on the pathophysiology of malignant ascites and describes the present and future options for refractory malignant ascites management.
恶性腹水是指与癌症相关的腹腔内液体蓄积。最常与腹水相关的肿瘤是卵巢癌、乳腺癌、结肠癌、胃癌和胰腺癌。症状包括腹胀、恶心、呕吐、厌食、呼吸困难和肢体水肿。可能涉及多种病理生理机制,如腹膜癌病、淋巴管阻塞、门静脉高压或心力衰竭。其诊断通常在已知肿瘤形成的背景下进行。恶性腹水与病情恶化相关。无法排出或早期复发且无法通过药物治疗预防的腹水被定义为难治性腹水。因此,难治性恶性腹水的管理是在姑息治疗的背景下进行的,旨在提高这些患者的生活质量。本综述列出了目前报道的关于恶性腹水病理生理学的数据,并描述了难治性恶性腹水管理的现状和未来选择。